CRISPR Therapeutics is trading around multiyear lows. Finding an undervalued growth stock can lead to some oversize returns in the long run. In some cases, it can be as simple as focusing on sectors of the market that might not be getting much attention of late, and thus could make for attractive under-the-radar investments right now. One stock that has been struggling and that arguably should be doing a lot better these days is CRISPR Therapeutics (CRSP 1.05%). There was a lot of excitement around the heal ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $45.71, demonstrating a +0.29% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Coming into today, shares of the company had gained 0.13% in the past month. In that same time, the Medical sector lost 3.6%, while the S&P 500 gained 1.21%. Analysts and investors alike will be ke ...

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. It's not fun missing out when a hot stock goes wild. The viral popularity of injectable diabetes and weight loss drugs, called GLP-1s, propelled pharmaceutical stock Novo Nordisk to over 350% in returns over the past five years. That sizeable return beat the broader market by a comfortable margin. But you needn't worry if you feel that you've missed out. The great thing about investing is th ...

Bargain hunters should love these great stocks. By most metrics, the stock market is priced at a premium these days. But that doesn't mean bargains can't still be found. Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (CRSP -2.65%), Gilead Sciences (GILD 0.05%), and Pfizer (PFE -0.81%). You can still get in on the ground floor Prosper Junior Bakiny (CRISPR Therapeutics): Valuing relatively small biotech compani ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%. The the stock of company has fallen by 0.8% in the past month, lagging the Medical sector's gain of 1.53% and the S&P 500's gain of 1.27%. Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming ea ...

There's a lot of growth on the way, and soon. CRISPR Therapeutics' (CRSP -0.56%) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. The innovative developer of gene therapies is making headway. And its pipeline implies a cornucopia of opportunities for the stock to rise over the coming years, especially if its cardiovascular medicine and oncology programs pan out. Still, investing in biotech companies isn't for the faint of heart, and even a s ...

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. In the past three years, CRISPR Therapeutics (CRSP -0.33%) has made tremendous progress. It was still a clinical-stage biotech in 2021, but it now has a gene-editing therapy that is approved in multiple countries. However, this regulatory milestone hasn't been accompanied by a strong stock market performance. CRISPR Therapeutics has significantly lagged the market since 2021. What is going on with this gene-editing ...

An investment in these players today could score a big win down the road. Why do investors love biotech stocks? Because these players often work on game-changing technology that could lead to tomorrow's game-changing treatment -- and potentially blockbuster revenue. As an investor, you often have to be patient, as it takes years for a company to bring a candidate through development and reach the billion-dollar revenue stage. And you have to be comfortable with a bit of risk too, because candidate failure a ...

Core Viewpoint - CRISPR Therapeutics has experienced a significant decline in stock price despite the potential of its gene-editing therapy, Casgevy, which could generate substantial revenue in the future [1][2][3] Group 1: Financial Performance - Year-to-date, CRISPR's shares are down 24%, far from its 52-week high of over $91 [1] - The company incurred a net loss of $243 million in the first half of the year, indicating ongoing financial challenges [4] - CRISPR has $2 billion in cash and cash equivalents, providing a solid financial foundation to sustain operations without immediate cash raises [4] Group 2: Product Pipeline and Market Potential - Casgevy, a treatment for sickle cell disease and beta thalassemia, is expected to generate billions in revenue, but analysts predict it won't exceed $1 billion until 2027 [2][3] - CRISPR is also developing other treatments, including CTX211 for type 1 diabetes and multiple cancer therapies, with preliminary data expected later this year [5][6] - The gene therapy market is currently valued at around $6 billion but is projected to grow to over $18 billion by the end of the decade [6] Group 3: Investment Outlook - CRISPR is viewed as a long-term investment opportunity, with a market capitalization of just over $4 billion, suggesting significant upside potential if additional treatments gain approval [7] - The company is not a typical high-risk biotech startup, as it has an approved treatment and ample liquid resources to support its operations [8] - Despite current market focus on artificial intelligence and tech stocks, CRISPR may present a compelling buy for patient investors, with the potential for substantial long-term returns [9]